Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Diabetes Metab Res Rev ; 34(6): e3010, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29637693

RESUMO

BACKGROUND: Oral insulin as a preventive strategy and/or treatment of type 1 diabetes has been the target of much research. Producing oral insulins is a complex and challenging task, with numerous pitfalls, due to physiological, physical, and biochemical barriers. Our aim was to determine the impact of oral insulin on the delicate gut microbiota composition. METHODS: Female nonobese diabetic mice were given oral porcine insulin 2 times a week from 5 weeks of age for 4 weeks, and then subsequently once a week for 21 weeks, or until euthanized. The mice were divided into groups on a gluten-reduced diet or a standard diet. Gut microbiota composition was analysed based on faecal samples, and the type 1 diabetes incidence of the mice was monitored. RESULTS: We observed no influence of the oral porcine insulin on the gut microbiota composition of mice on a gluten-reduced or a standard diet at 9 weeks of age. Also, the administration of oral insulin did not influence the incidence of type 1 diabetes at 30 weeks of age. CONCLUSIONS: Oral porcine insulin does not alter the gut microbiota composition of nonobese diabetic mice on either a gluten-reduced diet or standard diet. Also, the oral porcine insulin did not influence the incidence of type 1 diabetes in the groups.


Assuntos
Diabetes Mellitus Experimental/microbiologia , Diabetes Mellitus Tipo 1/microbiologia , Microbioma Gastrointestinal/efeitos dos fármacos , Insulina Regular de Porco/administração & dosagem , Administração Oral , Animais , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/imunologia , Diabetes Mellitus Experimental/patologia , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/patologia , Disbiose/imunologia , Disbiose/patologia , Fezes/microbiologia , Feminino , Insulina Regular de Porco/efeitos adversos , Camundongos , Camundongos Endogâmicos NOD , Suínos
2.
Indian J Pharmacol ; 47(2): 227-9, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25878390

RESUMO

Insulin is an important agent for the treatment of diabetes mellitus (DM). Allergic reactions to insulin therapy, although rare, have been evident since animal insulin became available for the treatment of DM in 1922. Hypersensitivity to insulin has considerably been reduced with the introduction of human insulin produced by recombinant deoxyribonucleic acid technology. Here, we present a case of Type 2 DM who demonstrated immediate (Type 1) hypersensitivity reaction on the sites of subcutaneous injection of soluble and isophane insulin but insulin glargine was tolerated well and provided good glycemic control.


Assuntos
Hipersensibilidade Imediata/induzido quimicamente , Insulina Glargina/efeitos adversos , Insulina Isófana/efeitos adversos , Insulina Regular de Porco/efeitos adversos , Adulto , Glicemia/análise , Feminino , Humanos , Hipersensibilidade Imediata/sangue , Hipersensibilidade Imediata/imunologia , Imunoglobulina E/sangue , Insulina Glargina/administração & dosagem , Insulina Glargina/uso terapêutico , Insulina Isófana/administração & dosagem , Insulina Isófana/uso terapêutico , Insulina Regular de Porco/administração & dosagem , Insulina Regular de Porco/uso terapêutico , Resultado do Tratamento
3.
Pediatr Diabetes ; 14(3): 211-6, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23350587

RESUMO

OBJECTIVE: There are an estimated 1000 children with diabetes in Tanzania. Recently, the first two pediatric endocrinologists, trained in the European Society for Paediatric Endocrinology (ESPE)/International Society for Paediatric and Adolescent Diabetes (ISPAD) program in Nairobi, Kenya, entered practice. The purpose of this study was to prospectively assess the impact of a 6-month diabetes management and education program on glycemic control and acute complications in children and adolescents in Tanzania. RESEARCH DESIGN AND METHODS: Eighty-one patients aged 3-19 yr were enrolled. All were on split-dose Insulatard (Neutral Protamine Hagedorn) and Actrapid (soluble, regular) insulin, and were given three glucose test strips per week. Children were seen in clinic an average of six times over 6 months and received 3 h of diabetes education. A structured questionnaire evaluated social demographic data and acute complications. RESULTS: Despite regular clinic attendance, diabetes education, and provision of insulin, hemoglobin A1c (HbA1c) levels did not improve. Four children (5%) had HbA1c 7.5%, 22 (28%) HbA1c 7.5-10%, 9 (24%) HbA1c 11-12.5%, and 36 (44%) HbA1c >12.5%. There was a substantial reduction in severe hypoglycemia, with 17% of subjects experiencing this acute complication compared to 52% in the 6 months prior to study enrolment. Six children were admitted in diabetic ketoacidosis during the study compared to three during the previous 6 months. Twenty-six children (36%) reported missing >6 doses of insulin (but only two lacked insulin). CONCLUSIONS: Diabetes education significantly reduced the risk of severe hypoglycemia, but better glycemic control of diabetes was not attained. Further study is needed to explore factors to improve glycemic control including increased testing, or perhaps different insulin regimens.


Assuntos
Diabetes Mellitus Tipo 1/terapia , Cetoacidose Diabética/prevenção & controle , Hiperglicemia/prevenção & controle , Hipoglicemia/prevenção & controle , Adolescente , Criança , Pré-Escolar , Estudos de Coortes , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 1/tratamento farmacológico , Cetoacidose Diabética/epidemiologia , Quimioterapia Combinada , Família , Feminino , Humanos , Hiperglicemia/epidemiologia , Hipoglicemia/epidemiologia , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/efeitos adversos , Hipoglicemiantes/uso terapêutico , Incidência , Insulina Isófana/administração & dosagem , Insulina Isófana/efeitos adversos , Insulina Isófana/uso terapêutico , Insulina Regular Humana/administração & dosagem , Insulina Regular Humana/efeitos adversos , Insulina Regular Humana/uso terapêutico , Insulina Regular de Porco/administração & dosagem , Insulina Regular de Porco/efeitos adversos , Insulina Regular de Porco/uso terapêutico , Insulina Isófana Humana , Masculino , Adesão à Medicação , Ambulatório Hospitalar , Educação de Pacientes como Assunto , Estudos Prospectivos , Tanzânia/epidemiologia
4.
J Med Primatol ; 42(1): 1-9, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23106308

RESUMO

BACKGROUND: Monkeys with insulin-dependent diabetes are important preclinical animal models for islet transplantation. Exogenous insulin should be administered to achieve good glycemic control and minimize the long-term vascular complications associated with diabetes until the graft function recovered completely. However, the effect of multiple daily injections of porcine or human insulin and the long-term effects of porcine insulin have not been studied in diabetic rhesus monkeys. METHODS: Diabetic rhesus monkeys, using a 6-month self-control insulin comparison experiment, were used to detect the incidence of adverse events and long-term diabetes complication events after long-term administration of porcine insulin. RESULTS: In this study, we found that a 20% higher dose of porcine insulin results in similar glycemic control as the human insulin regimen, and adverse events were seldom reported when porcine insulin was administered. Moreover, long-term injection with porcine insulin could delay the rate and severity of diabetes-related complications. CONCLUSIONS: Porcine insulin as a competent candidate for regular insulin therapy to maintain blood glucose levels in insulin-dependent diabetic monkeys during preclinical studies of islet transplantation.


Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Tipo 1/veterinária , Hipoglicemiantes/uso terapêutico , Insulina Isófana/uso terapêutico , Insulina Regular Humana/uso terapêutico , Insulina Regular de Porco/uso terapêutico , Animais , Glicemia , Diabetes Mellitus Tipo 1/tratamento farmacológico , Nefropatias Diabéticas , Retinopatia Diabética , Hemoglobinas Glicadas , Hipoglicemiantes/efeitos adversos , Hipoglicemiantes/economia , Insulina Isófana/efeitos adversos , Insulina Isófana/economia , Insulina Regular Humana/efeitos adversos , Insulina Regular Humana/economia , Insulina Regular de Porco/efeitos adversos , Insulina Regular de Porco/economia , Macaca mulatta , Doenças dos Macacos/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...